Diabetic patients using aspirin appeared to have a decreased risk of hormone receptor-positive breast cancer (IDs 111, 112), which aligns with findings from a meta-analysis of observational studies on prophylactic aspirin intake and breast cancer risk [94]. Here, NR4A1 is linked to breast carcinoma.